about

Board of Directors

Mr. Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm. Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc in late 2007. Prior to Kyphon, Mr. Mott held several executive positions at Wilson Greatbatch Technologies, Inc., most recently as Chief Operating Officer, as well as executive operating roles within the Bristol-Myers Squibb Company. Mr. Mott served as Chairman/Founder of Accendo, and Chairman of the Board of PhotoThera, Inc., both medical device companies investigating the use of light energy to treat various diseases and health conditions. Mr. Mott is the previous recipient of the Ernst & Young Entrepreneur of the Year Award and the Frost & Sullivan Technology Leadership of the Year Award. Mr. Mott holds a Bachelor of Science in ceramic engineering from Alfred University and is a graduate of Harvard University's Advanced Management Program.

Dr. Cheryl Blanchard joined Microchips Biotech in July 2014 as its Chief Executive Officer. She is a medical device and biologics executive with over 25 years of leadership experience. Most recently she was a corporate officer of Zimmer, Inc., a medical device company focused on musculoskeletal products, where she served as Senior Vice President, Chief Scientific Officer and general manager of Zimmer Biologics. During her 12 years with Zimmer, she operated in roles of increasing responsibility including global leadership of research and development, advanced technologies, clinical, quality and regulatory affairs, medical affairs, medical education, health economics, and reimbursement. She created, built and led the biologics business at Zimmer through disciplined execution of an R&D pipeline coupled with significant partnering and business development activities.

Prior to Zimmer, Dr. Blanchard built and led the medical device practice at Southwest Research Institute while also serving as an adjunct professor at the University of Texas Health Science Center, both in San Antonio, TX. Some of her work led to the creation of Keraplast Technologies, LLC. Dr. Blanchard brings a unique combination of results-oriented business management skills, technical leadership, and a track record of commercializing game-changing products that address unmet needs. In 2015, she was elected to the National Academy of Engineering, among the highest professional distinctions accorded to an engineer.

Dr. Blanchard holds a Bachelor of Science in Ceramic Engineering from Alfred University, and a Masters of Science and Ph.D. in materials science and engineering, both from the University of Texas at Austin.

Terry McGuire is a Founding Partner of Polaris Partners and brings more than 25 years of successful early-stage investing experience to the healthcare industry. As a venture capitalist, he has invested in more than 48 companies, co-founding three: Microchips Biotech, Inspire Pharmaceuticals and Advanced Inhalation Research. Mr. McGuire serves on the boards of Polaris-backed companies 480 Biomedical; The Gerngross Companies (Adimab, Arsanis & Allector); Iora Health; Microchips Biotech; Nextcode Health; Pulmatrix; Quantum Designs; SustainX, Acceleron (XLRN) and Ironwood Pharmaceuticals (IRWD). Mr. McGuire also chairs the Board of Overseers of the Thayer School of Engineering, Dartmouth College, and serves on the boards of MIT’s David Koch Institute for Integrative Cancer Research, the Arthur Rock Center for Entrepreneurship, Harvard Business School; and the Scientific Advisory Board at Brigham & Women’s Hospital. He is the founder and chairman of the Global Venture Capital Congress and Chairman Emeritus of the National Venture Capital Association. Mr. McGuire holds an MBA from Harvard Business School, a Master of Science in engineering from The Thayer School at Dartmouth College, and a Bachelor of Science in physics and economics from Hobart College.

Institute Professor
Massachusetts Institute of Technology

Robert Langer is an Institute Professor at MIT, the most prestigious distinction awarded to an elite group of 11 faculty members, and the co-founder of Microchips Biotech. Dr. Langer has an h-index of 202, the highest of any engineer in history, and more than 1,000 issued and pending patents, which have been licensed or sublicensed to over 250 companies.  Among his many accomplishments, Dr. Langer served as Chairman of the FDA’s prestigious Science Board from 1999-2002, and is one of only three individuals elected to the Institute of Medicine of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.  Dr. Langer is the recipient of several prestigious awards including the United States National Medal of Science and the United States National Medal of Technology and Innovation, the Charles Stark Draper Prize (considered the engineering Nobel Prize), the Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize, the Kyoto Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” Dr. Langer holds 22 honorary doctorates, including degrees from Harvard and Yale.

Professor of Materials Science and Engineering
Massachusetts Institute of Technology

Michael J. Cima is author or co-author of over 250 peer-reviewed scientific publications and 60 patents, and is a recognized expert in the field of materials processing and a member of the National Academy of Engineering. He is a faculty member at MIT and is actively involved in research of materials and engineered systems aimed at improving human health such as treatments for cancer, metabolic diseases, trauma and urological disorders. Dr. Cima's research includes advanced forming technologies for complex macro and micro devices, such as colloid science, MEMS and other micro components for medical devices that are used for drug delivery and diagnostics, as well as high-throughput development methods for formulations of materials and pharmaceutical formulations. He is a co-inventor of MIT's three-dimensional printing process. His research has led to the development of chemically derived epitaxial oxide films for HTSC-coated conductors. He and collaborators are developing implantable MEMS devices for unprecedented control in the delivery of pharmaceuticals and implantable diagnostic systems.  Dr. Cima co-founded Microchips Biotech.

Dan Sheehan manages the activities of Medtronic Ventures. Prior to the Medtronic acquisition of Covidien, he started and managed the activities of Covidien Ventures. Mr. Sheehan is passionate about working with the managers of entrepreneurial companies and understands the complexity of commercializing new medical technologies. His background includes both venture capital investing and operating company management roles in the healthcare sector. Prior to Medtronic, Mr. Sheehan was a General Partner with Affinity Capital Management, a healthcare oriented venture capital firm in Minneapolis. He has also managed the business development and strategic marketing efforts for Steris Corporation, a provider of infection prevention and surgical support products for the healthcare and life sciences sectors. He has been and continues to be a member of the Board of Directors of many portfolio companies. He is a graduate of Fordham University and Columbia Business School.

Charles Hutchinson served as director and president of GlycoFi after co-founding the company in 2000 until its acquisition by Merck in 2006. Prior to GlycoFi, Dr. Hutchinson served as a John H. Krehbiel Senior Professor for Emerging Technologies at the Thayer School of Engineering at Dartmouth and as the Dean of the Thayer School. Dr. Hutchinson serves on the board of directors for several companies and is a recognized leader in advanced technologies, both in academia and industry. Dr. Hutchinson received his PhD from Stanford, his Master of Science in mechanical engineering from Stanford and his Bachelor of Science in electrical engineering from the Illinois Institute of Technology.

 

Asaph Naaman serves as the Senior Vice President & Chief Financial Officer for Global R&D at Teva Pharmaceuticals. Serving on the leadership teams of both Global R&D and the Global Finance group, he oversees a budget in excess of $1.3 billion for an organization of more than 3,000 people. At Teva, Mr. Naaman leads the Finance R&D team in all finance business partnership activities and plays an instrumental role in the evaluation and prioritization of R&D projects and other key initiatives. He is pivotal in the business and financial planning process for Global R&D at Teva, including alternative funding programs. Prior to joining Teva, Mr. Naaman served as VP Global Corporate Development & Strategy in Better Place, having previously spent 12 years at FMCG giant, Proctor & Gamble, in various finance and business development roles, including Deal Manager, Corporate Mergers & Acquisitions. Mr. Naaman holds an Executive MBA degree from Northwestern University and Tel Aviv University and a Bachelor’s Degree in Economics and Management from Tel Aviv University.